All In Biotech

Drug Trial Radar · NCT07736937

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

A Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of TUB-040, in Combination With Standard Ovarian Cancer Drugs in Patients With High-grade Epithelial Serous or Endometrioid Epithelial Ovarian Cancer OC)

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 30, 2026

Primary completion

Mar 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • TUB-040 + Carbo + BEVDrug

    Ph1b: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety and tolerability of TUB-040 in combination with standard ovarian cancer drugsTime frame: From enrollment until 30 days after last study drug
  2. Maximum Tolerated Dose (MTD) of TUB-040 with standard of care (SOC) treatmentTime frame: Day 1 up to Day 21 of each treatment cycle

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Start Cal

    Los Angeles, California · Recruiting

  • Start Njeb

    East Brunswick, New Jersey · Recruiting

  • Start Nyli

    New York, New York · Recruiting

  • UCL Louvain

    Brussels, Belgium · Recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • CHU de Liege

    Liège, Belgium · Recruiting

  • ARENSIA Exploratory Medicine

    Kyiv, Ukraine · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.